KARPAS 299 Xenograft Model

KARPAS 299 xenograft model

The KARPAS 299 cell line (human lymphoma) is used to create the CDX (Cell Line Derived Xenograft) KARPAS 299 xenograft mouse model.  The KARPAS 299 xenograft model, a CD30+ cell line, allows for antibody drug conjugate testing (such as MMAE conjugated to anti-CD30).

Basic study design

  1. The cells, maintained at exponential growth, are collected for inoculation by trypsinization.  Viability and cell counts are determined by using trypan blue (98% min viability).
  2. The KARPAS 299 cell suspension concentration is adjusted to the density needed for inoculation.
  3. In a volume of 100 uL, one million cells (matrigel+KARPAS 299 suspension) is injected into hind leg flank of each mouse (NOD/SCID or athymic BALB/C, 10 to 12 weeks) subcutaneously (s.c).
  4. Calipers are used to measure tumors; average sizes of 50-150 mm3 allow the animals to be sorted into the treatment cohorts.
  5. Administration of test materials are given according to the treatment schedule.  Tumor measurements are recorded daily; mouse weights are recorded 3 times weekly.
  6. At the study’s tumor size limit, animals are euthanized and a necropsy is performed.  Tumors are removed, weight recorded and tumor documented (digital imaging).
  7. Collected tissues, by standard necropsy, can be: snap frozen in Liquid N2, submersed with RNAlater, isolated nucleic acids or prepared for histology.

Get Instant Quote for
KARPAS 299 Xenograft Model

Xenograft animal models are used to assess the effectiveness of drugs against specific types of cancer. New medicines are tested on staged tumor growths that have been engrafted via subcutaneous or orthotopic inoculation in an immunocompromised mouse or rat model. All clinically approved anti-cancer agents have been evaluated with conventional preclinical in vivo models. Xenograft studies can be highly complex, starting with the selection of the appropriate animal model, choice of tumorigenic cell line, administration method, dosing, analysis of tumor growth rates and tumor analysis (histology, mRNA and protein expression levels).

Altogen Labs provides an array of laboratory services using over 30 standard Cell Line Derived Xenograft (CDX) models and over 20 PDX models. Researchers investigating the role of specific proteins or gene products in regulating tumor growth can benefit from development of protein overexpression (genetically engineered to ectopically express proteins, tumor suppressors, or oncogenes) and RNAi cell lines with long term gene silencing. Altogen Labs provides quantitative gene expression analysis of mRNA expression (RT-PCR) and protein expression analysis using the WES system (ProteinSimple).

The dosing of the experimental compound of interest is initiated, for a staged study, when the mean tumor size reaches a specified volume (typically 50-100 mm3). In an unstaged study, the dosing of the compound of interest is initiated immediately after xenografting. Mice are dosed once or twice a day for 28 days (or other desired study duration) via the chosen route of administration. Tumor volume (mm3) is calculated via the “(W x W x L) / 2” formula, where W is tumor width and L is tumor length.

Animal handling and maintenance at the Altogen Labs facility is IACUC-regulated and GLP-compliant. Following acclimatization to the vivarium environment, mice are sorted according to body mass. The animals are examined daily for tumor appearance and clinical signs. We provide detailed experimental procedures, health reports and data (all-inclusive report is provided to the client that includes methods, results, discussion and raw data along with statistical analysis). Additional services available include collection of tissue, histology, isolation of total protein or RNA and analysis of gene expression. Our animal facilities have the flexibility to use specialized food or water systems for inducible gene expression systems.

Following options are available for the KARPAS 299 xenograft model:

  • KARPAS 299 Tumor Growth Delay (TGD; latency)
  • KARPAS 299 Tumor Growth Inhibition (TGI)
  • Dosing frequency and duration of dose administration
  • Dosing route (intravenous, intratracheal, continuous infusion, intraperitoneal, intratumoral, oral gavage, topical, intramuscular, subcutaneous, intranasal, using cutting-edge micro-injection techniques and pump-controlled IV injection)
  • KARPAS 299 tumor immunohistochemistry
  • Alternative cell engraftment sites (orthotopic transplantation, tail vein injection and left ventricular injection for metastasis studies, injection into the mammary fat pad, intraperitoneal injection)
  • Blood chemistry analysis
  • Toxicity and survival (optional: performing a broad health observation program)
  • Gross necropsies and histopathology
  • Positive control group employing cyclophosphamide, at a dosage of 50 mg/kg administered by intramuscular injection to the control group daily for the study duration
  • Lipid distribution and metabolic assays
  • Imaging studies: Fluorescence-based whole body imaging, MRI

Get Instant Quote for
KARPAS 299 Xenograft Model